Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Post-Market Evaluation of the EVO ICL

← catalyst calendar

NCT05538754 · results posted

Sponsored by Staar Surgical Company (industry) · STAA — their whole pipeline →.

Phase
Not applicable
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
205actual
Sites
8
Country
United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-27

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2022-09-23actualWhen the study began enrolling
Primary completion2023-09-21actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2023-10-04actualThe whole study's end, after follow-up
First posted2022-09-14actualWhen this record first appeared on the registry
Results posted2024-12-03actualWhen the sponsor posted results to the registry
Record updated2026-03-05actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Myopia
  • Myopic Astigmatism

Intervention

  • Device: EVO ICL

Primary outcomes

what the primary-completion date above is the date OF
Elevated Intraocular Pressure (IOP) in Primary Eyes ≥ 30 mmHg
measured 1-6 hours postoperatively
Elevated Intraocular Pressure (IOP) in Primary Eyes ≥ 40 mmHG
measured 1-6 hours postoperatively

Posted documents

hosted by the registry — we link, never re-serve
Study Protocol and Statistical Analysis Planposted 2023-04-25 · 837 KB · Prot_SAP_000.pdf

Related

STAA · their whole pipeline

STAA's other studiesmost recently updated first

Permalink · STAA's whole pipeline · Catalyst calendar · Every registered study · What changed